Carrie L. Bourdow
CIK 1638989 · Acting CEO · last filed 2024-10-10
Carrie L. Bourdow is an Acting CEO who has filed 39 SEC Form 4 insider transactions across 3 companies since 2015. Across all open-market trades the lifetime net is +$115.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $7.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.1K
3
39
$115.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVN | President & CEO | 642,923 | $0.01 | $7.1K | $117.9K | 26 | 2023-12-15 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 9,933 | $1.42 | $14.1K | -$2.4K | 8 | 2022-08-03 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | 40,000 | $12.58 | $503.0K | $0 | 4 | 2022-06-24 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-10 | — | Tax (F) | −1,822 | -$2.7K | |
| 2023-12-15 | TRVN | Mixed | +462,877 | $282.4K | EDGAR |
| 2023-12-05 | TRVN | Tax (F) | −12,028 | -$7.1K | EDGAR |
| 2023-01-06 | TRVN | Grant (A) | +100,000 | $0 | EDGAR |
| 2022-12-20 | TRVN | Tax (F) | −1,342 | -$2.1K | EDGAR |
| 2022-12-06 | TRVN | Tax (F) | −3,560 | -$12.2K | EDGAR |
| 2022-08-03 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −8,540 | -$1.5K | EDGAR |
| 2022-06-24 | Carisma Therapeutics Inc. (SESN) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2021-12-21 | TRVN | Tax (F) | −33,546 | -$23.5K | EDGAR |
| 2021-12-08 | TRVN | Tax (F) | −93,561 | -$60.8K | EDGAR |